Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
2,643.00
-11.00 (-0.41%)
Nov 18, 2026, 3:30 PM JST
Rohto Pharmaceutical Revenue
Rohto Pharmaceutical had revenue of 87.38B JPY in the quarter ending September 30, 2026, with 6.18% growth. This brings the company's total for the last twelve months to 358.47B, up 7.39% year-over-year. In the fiscal year ending March 31, 2026, Rohto Pharmaceutical had annual revenue of 343.73B with 11.37% growth. That makes Rohto Pharmaceutical the 4,639th largest company in the world by revenue and 463rd in Japan.
Revenue (ttm)
358.47B
Revenue Growth
+7.39%
P/S Ratio
1.66
Revenue / Employee
38.58M
Employees
9,292
Market Cap
594.48B
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Rohto Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 343.73B | 35.10B | 11.37% |
| Mar 31, 2025 | 308.63B | 37.79B | 13.95% |
| Mar 31, 2024 | 270.84B | 32.18B | 13.48% |
| Mar 31, 2023 | 238.66B | 39.02B | 19.54% |
| Mar 31, 2022 | 199.65B | 18.36B | 10.13% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shiseido Company | 1.02T |
| Unicharm | 980.39B |
| Lion Corporation | 442.56B |
| KOSE Holdings | 339.11B |
| Earth | 185.22B |
| Pola Orbis Holdings | 171.96B |
| Kobayashi Pharmaceutical | 167.20B |
| MTG Co., Ltd. | 143.56B |
Rohto Pharmaceutical News
- 6 days ago - Rohto Pharmaceutical Quarterly report: Q2 2027 - Filings
- 6 days ago - Rohto Pharmaceutical Slides: Q2 2027 - Filings
- 16 days ago - Drug maker Rohto plans clinical trials in Hong Kong as OASESā first Japan partner - South China Morning Post
- 6 weeks ago - Rohto Pharmaceutical Slides: Investor presentation - Filings
- 3 months ago - Rohto Pharmaceutical Quarterly report: Q1 2027 - Filings
- 3 months ago - Rohto Pharmaceutical Slides: Q1 2027 - Filings
- 6 months ago - Rohto Pharmaceutical Slides: Q4 2026 - Filings
- 6 months ago - Rohto Pharmaceutical Quarterly report: Q4 2026 - Filings